Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration

Regeneron, listening to the call for more gene therapies, has added hearing loss specialist Decibel Therapeutics to its playlist in a deal valuing the biotech at $109 million at closing.